

**UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF FLORIDA
FORT LAUDERDALE DIVISION**

JERRY LOWRY, on behalf of himself
and all others similarly situated,

Plaintiff,

v.

ANDRX CORPORATION, and
THOMAS P. RICE,

Defendants.

CASE NO.: 05-61640-CIV-DIMITROULEAS

NOTICE OF PENDENCY OF PROPOSED CLASS ACTION AND ITS SETTLEMENT

IF YOU BOUGHT COMMON STOCK OF ANDRX CORPORATION (“ANDRX” OR THE “COMPANY”) ON THE OPEN MARKET BETWEEN MARCH 9, 2005 AND SEPTEMBER 5, 2005, INCLUSIVE, YOU MAY BE ENTITLED TO RECEIVE A PAYMENT FROM THIS PROPOSED CLASS ACTION SETTLEMENT (THE “SETTLEMENT”).

**A FEDERAL COURT AUTHORIZED THIS NOTICE.
THIS IS NOT A SOLICITATION FROM A LAWYER.**

- This Notice concerns the proposed settlement of claims (“Settlement”) asserted by lead plaintiff (“Lead Plaintiff”) in this consolidated class action (the “Action”) against defendants Andrx and Thomas P. Rice (collectively, “Defendants”). The Action is pending in the United States District Court for the Southern District of Florida (the “Court”) against Defendants by open market purchasers of Andrx common stock suing on behalf of themselves and others allegedly damaged by Defendants’ alleged violations of the federal securities laws.
- The Settlement will result in a payment of \$8,000,000 in United States currency, plus accrued interest but minus attorneys’ fees, costs, and other expenses, for the benefit of investors who bought shares of Andrx common stock on the open market between March 9, 2005 and September 5, 2005, inclusive (the “Class Period”) and who suffered a loss (the “Settlement Class;” members of the Settlement Class are “Settlement Class Members”). The recovery is explained in greater detail below.
- You are hereby notified that a hearing (the “Fairness Hearing”) will be held before the Honorable William P. Dimitrouleas, United States District Judge, United States District Court for the Southern District of Florida, on April 3, 2008 at 1:00 p.m., to determine whether the Settlement is fair, reasonable, and adequate, and should be finally approved by the Court, along with other items addressed herein.
- Your legal rights will be affected whether you act or do not act. Read this Notice carefully.

| YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT | | |
|---|---|--|
| WHAT YOUR OPTIONS ARE | WHAT YOU MUST DO FOR EACH OPTION | DATE BY WHICH YOU MUST ACT |
| SUBMIT A CLAIM FORM | The only way to get a payment. | The deadline to submit a claim form is April 10, 2008. |
| EXCLUDE YOURSELF | You get no payment. This is the only option that allows you to be part of any other lawsuit against Defendants and other Released Parties about the legal claims in the Action. | The deadline to exclude yourself is March 14, 2008. |
| OBJECT | Write to the Court about why you do not like the Settlement, the Plan of Allocation, and/or Lead Counsel’s request for attorneys’ fees and reimbursement of expenses. | The deadline to object is March 14, 2008. |
| GO TO THE FAIRNESS HEARING | Ask to speak in Court about the fairness of the Settlement, the Plan of Allocation, and/or the request for attorneys’ fees and reimbursement of expenses. | The Fairness Hearing will take place on April 3, 2008 at 1:00 p.m. |
| DO NOTHING | You get no payment and you give up any rights. | N/A |

- These rights and options—and the deadlines by which to exercise them—are explained in this Notice.
- The Court has not yet certified this Action as a class action or approved the Settlement. Payments to the Settlement Class will be made if the Court certifies the Settlement Class and approves the Settlement; after appeals, if any, are resolved; and after the claims processing procedure is complete.

Statement Of Recovery:

Lead Plaintiff has entered into an agreement to settle the Action that will resolve the claims of Lead Plaintiff and the Settlement Class against Defendants. The Settlement described herein will create a fund consisting of \$8,000,000 in cash plus accrued interest (the “Settlement Fund”). The Settlement Fund will be used for the settlement of the Action, and the payment of taxes, tax expenses, settlement administration costs (including the costs of notice in the Action), and attorneys’ fees and expenses. The cash remaining after the expenditures for settlement administration costs, taxes, tax expenses and attorneys’ fees and expenses will be the “Net Settlement Fund.”

Lead Plaintiff’s financial expert calculated that approximately 25.93 million shares of Andrx common stock traded on the open market during the Class Period. Assuming that all members of the Settlement Class who held affected shares elect to participate in the Settlement, Lead Plaintiff estimates that the recovery would be approximately \$0.31 per damaged share.

The following factors will also affect the actual recovery per damaged share: (1) the number of claims filed; (2) when Settlement Class Members purchased the shares during the Class Period; (3) whether Settlement Class Members sold their shares during the Class Period, or held their shares past the end of the Class Period; (4) the number of shares sold privately that were sold over the open market during the Class Period; (5) administration costs, including the costs of notice; and (6) the amount awarded by the Court for attorneys’ fees, costs and expenses. Distributions to Settlement Class Members pursuant to the terms of the Settlement, upon approval by the Court, will be made based on a formula described below.

Statement Of Potential Outcome:

This Action was brought against Defendants and others for alleged misstatements and other conduct related to Andrx which were alleged to have occurred starting on March 9, 2005. While the Action survived a motion to dismiss, Lead Plaintiff and Defendants disagree on liability, damages, and the average amount of damages per share (if any) that would be recoverable if Lead Plaintiff were to prevail ultimately. Defendants deny that they are liable to Lead Plaintiff or the Settlement Class in any respect and deny that Lead Plaintiff or the Settlement Class have suffered any damages.

Lead Plaintiff’s financial expert estimates that if Settlement Class Members were to prevail on the claims that remain in the proposed class action, the maximum recoverable damages would be approximately \$44.295 million. Thus, the \$8,000,000 settlement amount represents approximately 18% of the maximum possible recovery.

Statement Of Attorneys’ Fees And Costs Sought:

Court-appointed Lead Counsel for the Lead Plaintiff, Murray, Frank & Sailer LLP (“Lead Counsel”) intends to apply to the Court for an award of attorneys’ fees not to exceed 30% of the Settlement Fund (including a *pro rata* share of accrued interest), and for reimbursement of reasonable costs and expenses necessarily incurred in bringing the Action, exclusive of settlement administration costs, in a total amount not to exceed \$175,000. The requested fees and expenses, excluding administration costs, would amount to an average of \$0.10 per damaged share. If the Settlement is approved, the costs of administering the Settlement will also be paid from the Settlement Fund.

Procedural History:

On September 6, 2005, Andrx announced that the Food & Drug Administration (“FDA”) had classified Andrx as Official Action Indicated (“OAI”). The OAI classification suspended FDA approval of all of the Company’s pending drug applications. That day, the Company’s stock price dropped 17%, from a closing price on September 5, 2005 of \$17.94 to \$14.89 on September 6, 2005.

On October 11, 2005, Jerry Lowry filed this action as a proposed class action in the United States District Court for the Southern District of Florida, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

In an order dated January 17, 2006, the Court appointed Pioneer Investment Management SGR SPA (“Pioneer”) as Lead Plaintiff and approved its selection of Murray, Frank & Sailer LLP as Lead Counsel. On June 23, 2006, Pioneer filed the operative amended complaint (“Complaint”). The Complaint alleged that Defendants had told investors that Andrx was complying with FDA regulations and expected to receive FDA approval for 30 new and pending drug

applications. The Complaint further alleged that the Defendants’ statements were false and misleading because Andrx was experiencing serious compliance deficiencies that had been identified by the FDA in its 2004 inspections of Andrx’s sole generic drug manufacturing facility, the Davie Facility. The Complaint alleged that those compliance deficiencies were magnifying, not improving, and that Andrx was not putting the needed resources into updating equipment, training, and other aspects of the manufacturing processes at the Davie Facility to bring Andrx into FDA compliance, despite Andrx’s public pledge to the FDA of corrective action.

On July 24, 2006, Defendants moved to dismiss the Complaint. After the parties fully briefed the motion, the Court heard oral argument and on December 7, 2006, entered an Order granting Defendants’ motion to dismiss in part and denying it in part. The Court sustained claims regarding Defendants’ statements about its manufacturing operations, but dismissed claims regarding Defendants’ statements about Andrx’s ability to obtain approval for new generic drugs.

On December 22, 2006, Defendants answered the Complaint and also asserted seventeen affirmative defenses. Subsequently, both parties engaged in extensive fact discovery. Lead Counsel has received hundreds of thousands of documents produced by both Defendants and various third parties.

On April 13, 2007, Pioneer moved to withdraw as Lead Plaintiff and Mr. Marley moved to substitute himself as Lead Plaintiff. On April 17, 2007, the Court granted Mr. Marley’s motion and appointed him Lead Plaintiff.

On April 18, 2007, Mr. Marley moved to certify the Action as a class action. Defendants opposed that motion and deposed Mr. Marley and another proposed class representative. Briefing on this motion was fully submitted at the time this Action settled, but the Court had not yet issued an order.

Settlement Negotiations:

Settlement negotiations between Lead Plaintiff and Defendants took place at a mediation with mediator Nicholas Politan, a retired federal judge, held on October 2, 2007. A settlement in principle was reached at this mediation.

Defendants deny and continue to deny that they have committed any act or omission giving rise to any liability or violation of law. The Settlement is therefore without admission of fault or liability on the part of any Defendant. Neither the agreement to settle nor the fact of settlement, whether consummated or not, nor any proceedings taken pursuant to the Settlement, shall be construed as an admission of liability or an admission of any claim or defense on the part of any party, in any respect. Moreover, neither the agreement to settle nor the fact of settlement, nor any proceedings taken pursuant to the Settlement, shall be admissible in any action, suit, proceeding, or investigation as evidence or as an admission of any claim or liabilities; provided, however, that any party to the Settlement may use the Settlement to the extent necessary to enforce any right conferred on that party by the Settlement.

Reasons For The Settlement:

Lead Counsel recommends the Settlement to the Settlement Class based on its evaluation of the claims asserted, the procedural posture of the Action (including the dismissal, in part, of the Action on December 7, 2006), the evidence developed, and the damages that might be proven by the Settlement Class. Lead Plaintiff has agreed to settle the claims raised in the Action pursuant to the terms and provisions of the Stipulation of Settlement (“Stipulation”) dated December 7, 2007 and filed with this Court, after considering (a) the substantial benefit to the Class that will be received as a result of this Settlement, compared to the expense and the inherent problems of proof under and possible defenses to the federal securities law violations asserted in the Action; and (b) Defendants’ ability to fund a settlement, if the litigation continues to proceed.

WHAT THIS NOTICE CONTAINS

| | |
|---|----------|
| | Page |
| BASIC INFORMATION. | 4 |
| 1. Why did I receive this Notice Package? | 4 |
| 2. Why is the Action a class action? | 4 |
| 3. Why is there a Settlement? | 4 |
| 4. How do I know if I am a Settlement Class Member? | 4 |
| 5. Are there exceptions to being included? | 4 |
| 6. I am still not sure if I am included. | 5 |
| 7. What does the Settlement of the Class Action provide? | 5 |
| 8. How much will my payment be? | 5 |
| 9. How will the Net Settlement Fund be allocated? | 5 |
| 10. How can I receive a payment pursuant to the Settlement? | 6 |
| 11. When will I get my payment? | 6 |

- 12. What am I releasing to receive a payment in this Settlement? 6
- 13. How do I exclude myself from the Settlement? 7
- 14. If I do not exclude myself, can I sue Defendants or the Released Parties for the same thing later? 8
- 15. Do I have a lawyer in the Action? 8
- 16. How will Lead Counsel be paid? 8
- 17. How do I tell the Court that I do not like the Settlement? 8
- 18. What is the difference between objecting and excluding? 8
- 19. When and where will the Court decide whether to approve the Settlement, the Plan of Allocation, and Lead Counsel’s request for attorneys’ fees and reimbursement of expenses? 8
- 20. Do I have to come to the Fairness Hearing? 9
- 21. May I speak at the Fairness Hearing? 9
- 22. What will happen if I do nothing at all? 9
- 23. Are there more details about the Settlement? 9
- 24. How do I get more information? 9

SPECIAL NOTICE TO SECURITIES BROKERS AND OTHER NOMINEES 9

BASIC INFORMATION

1. Why did I receive this Notice Package?

The Court authorized this Notice and Proof of Claim and Release (the “Notice Package”) to be sent to you because you or someone in your family may have purchased shares of Andrx common stock on the open market between March 9, 2005 and September 5, 2005, both dates inclusive. If this description applies to you or someone in your family, you have a right to know about the proposed Settlement, and about all of your options, before the Court decides whether to approve the Settlement.

If the Court approves the Settlement and after objections and appeals, if any, are resolved, an administrator appointed by the Court will distribute the payments to Settlement Class Members who submitted valid claims.

This Notice Package explains the lawsuit, the Settlement, your legal rights, what benefits are available, who is eligible for them, and how to get them. The sending of this Notice Package is not an expression of any opinion by the Court about the merits of any of the claims or defenses asserted by any party in the Action or the fairness or adequacy of the proposed Settlement.

2. Why is the Action a class action?

This Action is a “class action” because Lead Plaintiff sued on behalf of other people and entities that purchased Andrx common stock over the open market during the Class Period and who had similar claims. Collectively, all these people comprise the Settlement Class and are Settlement Class Members. The Court will resolve the issues for all Settlement Class Members, except for those who exclude themselves from the Settlement Class.

3. Why is there a Settlement?

The Court did not ultimately decide in favor of either Lead Plaintiff and the Settlement Class or Defendants. Instead, the parties agreed to the Settlement. That way, they avoid the risks, costs and delay of a trial, and the people affected will receive compensation. Lead Plaintiff and Lead Counsel believe the Settlement is in the best interests of all Settlement Class Members.

Accordingly, Lead Plaintiff and Defendants have entered into the Settlement. Under this Settlement, a fund was established to provide compensation to Settlement Class Members. How the proceeds obtained under the Settlement will be distributed is discussed below.

4. How do I know if I am a Settlement Class Member?

Under the Settlement, and subject to the exceptions explained below, the persons who are Settlement Class Members are: All persons who purchased shares of Andrx common stock on the open market between March 9, 2005 and September 5, 2005, both dates inclusive.

5. Are there exceptions to being included?

People who are automatically excluded from the Settlement Class are: Defendants, members of the immediate family of defendant Rice, any subsidiary, affiliate, or successor-in-interest of Andrx, and the directors and officers of Andrx or its subsidiaries, affiliates or successor-in-interest, or any entity in which any excluded person has a controlling interest, and the legal representatives, heirs, successors and assigns of any excluded person.

If one of your mutual funds owns shares of Andrx common stock, that alone does not make you a Settlement Class Member. You are a Settlement Class Member only if you individually purchased shares of Andrx common stock on the open market during the period between March 9, 2005 and September 5, 2005, inclusive. Contact your broker to see if you hold or have held Andrx common stock.

If you sold Andrx common stock between March 9, 2005 and September 5, 2005, inclusive, that alone does not make you a Settlement Class Member. You are a Settlement Class Member only if you bought shares of Andrx common stock on the open market during the Class Period.

6. I am still not sure if I am included.

If you are still not sure whether you are included, you can ask for free help. You can contact the Claims Administrator by telephone at (866) 274-4004, by fax at (610) 565-7985, by accessing www.strategicclaims.net, or you can fill out and return the claim form below to see if you qualify.

7. What does the Settlement of the Class Action provide?

Defendants have agreed to create a Settlement Fund of \$8,000,000 for the benefit of Settlement Class Members. The balance of the fund, after deduction of taxes, tax expenses, administration costs (including the costs of publishing this notice) and Court-awarded attorneys' fees and expenses, will be allocated proportionately among all Settlement Class Members who send in a valid Proof of Claim and Release form ("Proof of Claim").

8. How much will my payment be?

If you are entitled to a payment, your proportionate share of the Net Settlement Fund will depend on the number of valid Proofs of Claim that Settlement Class Members submit, how many shares of Andrx common stock you bought, and when you bought and sold them. The proposed plan to distribute the Net Settlement Fund to the Settlement Class (the "Plan of Allocation") is set forth below.

For each Settlement Class Member that submits a valid Proof of Claim (an "Authorized Claimant"), the Claims Administrator will determine the Authorized Claimant's *pro rata* share of the Net Settlement Fund based upon that Authorized Claimant's "Recognized Loss." The Recognized Loss formula is not intended to be an estimate of the amount of what a Settlement Class Member lost or might have been able to recover after a trial; nor is it an estimate of the amount that will be paid to Authorized Claimants pursuant to the Settlement. The Recognized Loss formula is the basis upon which the Net Settlement Fund will be proportionately allocated to the Authorized Claimants, and will be computed in accordance with the Plan of Allocation.

It is unlikely that you will receive a payment for all of your Recognized Loss. After all Settlement Class Members have sent in their claim forms, the payment you receive will reflect your Recognized Loss in relation to the total of all Authorized Claimants' Recognized Losses. Generally, those who bought more shares and have a larger Recognized Loss will get more money, and those who bought fewer shares and have a smaller Recognized Loss will get less. The number of claimants who send in claims varies widely from case to case.

9. How will the Net Settlement Fund be allocated?

The proposed Plan of Allocation provides recovery for the decline in the price of Andrx shares between March 9, 2005 and September 5, 2005, inclusive. On July 28, 2005, after the close of trading, Andrx issued a press release that disclosed, among other things, that the FDA had issued a Form 483 report following the conclusion of its inspection of Andrx starting in May 2005. The price of Andrx stock dropped 11%, from \$20.84 to \$18.55 after the release of this press release. Lead Plaintiffs' financial expert attributes \$0.33 of that stock price drop to the disclosure of Andrx's FDA compliance problems. On September 5, 2005, Andrx stock closed at \$17.94. Thereafter, before the market opened, Andrx announced that it had been placed on OAI status. The Company's stock price dropped 17% in one day to close at \$14.89 on September 6, 2005. Lead Plaintiff's financial expert estimates that this drop of \$3.05 per share represents the artificial inflation caused by Defendants' alleged misrepresentations.

The Plan of Allocation provides different levels of recovery for Settlement Class Members, which are based on the dates the shares of Andrx common stock were purchased and sold.

Based on the foregoing, and for purposes of this Settlement only, "Recognized Loss" will be calculated as follows:

1. For shares purchased on the open market between March 9, 2005 and July 28, 2005, inclusive, and:
 - a. sold prior to the close of trading on July 28, 2005, the Recognized Claim is \$0.00 (zero), because these shares were purchased and sold with the same inflation;
 - b. sold between July 29, 2005 and September 5, 2005, inclusive, the recognized claim is the lesser of: i) the purchase price minus the sales price; or ii) \$0.33 per share;
 - c. sold between September 6, 2005 and December 4, 2005, inclusive, the Recognized Claim is the lesser of: i) the purchase price minus the mean trading price on the date of sale, calculated consistent with

section 21D(e) of the Private Securities Litigation Reform Act, 15 U.S.C. § 78u-4(e) (“PSLRA mean trading price”); or ii) \$2.37 per share; or

- d. held as of the close of trading on December 4, 2005, the Recognized Claim is the lesser of: i) the purchase price minus \$15.90; or ii) \$2.37 per share.
2. For shares purchased on the open market between July 29, 2005 and September 5, 2005, inclusive, and:
 - a. sold prior to September 6, 2005, the Recognized Claim is \$0.00 (zero), because these shares were purchased and sold with the same inflation;
 - b. sold between September 6, 2005 and December 4, 2005, inclusive, the Recognized Claim is the lesser of: i) the purchase price minus the PSLRA mean trading price on the date of sale; or ii) \$2.04 per share; or
 - c. held as of the close of trading on December 4, 2005, the Recognized Claim is the lesser of: i) the purchase price minus \$15.90; or ii) \$2.04 per share.

General Provisions:

1. The date of purchase or sale is the “contract” or “trade” date and not the “settlement” date.
2. In processing claims, the first-in, first-out basis (“FIFO”) will be applied to purchases and sales.
3. The covering purchase of a short sale is not an eligible purchase.
4. Brokerage commissions, fees, and taxes should be excluded in the purchase and sale prices of Andrx common stock.
5. Where shares were purchased/sold by reason of having exercised an option, the premium should be incorporated into the price accordingly.
6. Gains will be omitted to determine the Recognized Loss of each Authorized Claimant.
7. No cash payment will be made on a claim where the distribution amount is less than \$10.
8. The Court has reserved jurisdiction to allow, disallow, or adjust the claim of any Settlement Class Member on equitable grounds.
9. No person shall have any claim against Lead Counsel, the Claims Administrator or such other agent designated by Lead Counsel, based on the distribution made substantially in accordance with the Stipulation and this Plan of Allocation, or further orders of the Court. In addition, no person shall have any claim against Defendants, Released Parties or Defendants’ Counsel with respect to the management, investment or distribution of the Net Settlement Fund.
10. Each Authorized Claimant shall be allocated a *pro rata* share of the Net Settlement Fund based on his, her, or its Recognized Loss as compared to the total Recognized Losses of all Authorized Claimants.
11. Settlement Class Members who do not submit acceptable Proofs of Claim will not share in the settlement proceeds. Settlement Class Members who neither submit a request for exclusion nor submit an acceptable Proof of Claim will nevertheless be bound by the Settlement and the Order and Final Judgment of the Court dismissing this Action.

10. How can I receive a payment pursuant to the Settlement?

To qualify for a payment in the Action, you must send in a Proof of Claim. A Proof of Claim accompanies this Notice. Read the instructions carefully, fill out the form, include all the documents the form asks for, sign it, and mail it postmarked **no later than April 10, 2008**.

11. When will I get my payment?

The Court will hold the Fairness Hearing on April 3, 2008 at 1:00 p.m., to decide whether to approve the Settlement. If the Court approves the Settlement, there may be appeals. It is always uncertain whether these appeals can be resolved, and resolving them can take time, perhaps more than a year. It also takes time for all the submitted Proofs of Claim to be processed. When this is completed and the Court approves Lead Plaintiff’s request for distribution of the Net Settlement Fund to the Authorized Claimants, payments will be mailed out in accordance with the Court’s order.

12. What am I releasing to receive a payment in this Settlement?

If you are a Settlement Class Member, unless you exclude yourself, you are remaining in the Action, which means that, if the Settlement is approved, you will release all “Released Claims” (as defined below) against Defendants Andrx, Thomas P. Rice and the “Released Parties” (as defined below).

“Released Claims” means any and all claims, demands, rights, causes of action or liabilities, of every nature and description whatsoever, whether based in law or equity, on federal, state, local, statutory or common law, or any other law, rule or regulation, known or Unknown Claims (as defined herein), accrued or not accrued, at law or in equity, which have been or could have been asserted individually by any Plaintiff and/or any Class Member in the Action against Defendants or any Released Parties which relate to, arise out of, or are based upon (a) any open market purchase of Andrx common stock during the Class Period and (b) the facts, matters, transactions or circumstances alleged or that could have been alleged in the Action.

“Unknown Claims” means any Released Claims which any Settling Party, and any or all other Persons and entities whose claims are being released, does not know or suspect to exist in his, her or its favor at the time of the release of the Released Parties which, if known by him, her, or it, might have affected his, her, or its settlement with and release of the Released Parties, or might have affected his, her, or its decision not to object to this settlement. Upon the Effective Date, the Settling Parties, and all other Persons and entities whose claims are being released, shall be deemed to have, and shall have, expressly waived and relinquished, to the fullest extent permitted by law, the provisions, rights and benefits of §1542 of the California Civil Code, which provides as follows:

A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.

The Lead Plaintiffs and Defendants have, and each of the Class Members shall be deemed to have and—by operation of the Judgment—shall have, expressly waived any and all provisions, rights and benefits conferred by any law of any state or territory of the United States, or principle of common law, which is similar, comparable and equivalent to California Civil Code §1542. The Settling Parties may hereafter discover facts in addition to or different from those which he, she, or it now knows or believes to be true with respect to the subject matter of the Released Claims, but Lead Plaintiff shall expressly and each Class Member, upon the Effective Date, shall be deemed to have, and—by operation of the Judgment—shall have, fully, finally, and forever settled and released any and all Released Claims, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts. Lead Plaintiff and Defendants acknowledge, and the Class Members shall be deemed by operation of the Judgment to have acknowledged, that the foregoing waiver of Unknown Claims was separately bargained for and a key element of the settlement of which this release is a part.

“Released Parties” means Defendants and the Related Parties. “Related Parties,” as defined in the Stipulation, means as to Andrx, each of Andrx’s past or present directors, officers, employees, agents, insurers, attorneys, accountants or auditors, legal representatives, predecessors, successors-in-interest, parents (including Watson Pharmaceuticals Inc.), subsidiaries, divisions, joint ventures, assigns, or any entity in which Andrx has a controlling interest; and means, as to Thomas P. Rice, any member of his immediate family, spouse, insurer, heir, or any trust of which Rice is the settler or which is for the benefit of Rice and/or member(s) of his family.

13. How do I exclude myself from the Settlement?

You can exclude yourself from the Settlement. If you are a Settlement Class Member and you do not want a payment from this Settlement, but you want to keep the right to sue or continue to sue any of the Defendants or the Released Parties on your own over the claims, known or unknown, being released in this Settlement, then you **must** take steps to exclude yourself from the Settlement. This is referred to as “opting out” of the Settlement Class.

To exclude yourself from the Settlement, you must send a letter by first class U.S. mail, postage prepaid, stating that you wish to be excluded from the Action. Your letter should include the date(s), price(s), and number(s) of shares of all purchases and sales of Andrx common stock during the Class Period. In addition, be sure to sign the letter, and to include your name, address, and telephone number in the letter. **No request for exclusion will be considered valid unless all of this information is included in the request.**

You must mail your exclusion request postmarked **no later than March 14, 2008** to the Claims Administrator at:

Andrx Corporation Securities Litigation
c/o Strategic Claims Services
600 North Jackson Street, Suite 3
P.O. Box 230
Media, PA 19063
www.strategicclaims.net

You cannot exclude yourself by telephone or by e-mail. If you properly exclude yourself, you will not get any Settlement payment, and you cannot object to the Settlement. You will not be legally bound by anything that happens in this lawsuit.

14. If I do not exclude myself, can I sue Defendants or the Released Parties for the same thing later?

No. Unless you exclude yourself, you give up any rights to sue Defendants or the Released Parties for the claims being released pursuant to this Settlement. If you have a pending lawsuit, speak to your lawyer in that case immediately. You must exclude yourself from the Settlement Class to continue your own lawsuit. **Remember, the exclusion deadline is March 14, 2008.**

15. Do I have a lawyer in the Action?

The Court ordered that Lead Counsel, Murray, Frank & Sailer LLP, represents you and the other Settlement Class Members in the Action. You will not be charged for the work done by Lead Counsel. If you want to be represented by your own lawyer, you may hire one at your own expense.

16. How will Lead Counsel be paid?

Lead Counsel has yet to be compensated for legal services rendered. Lead Counsel is asking the Court to award attorneys' fees from the Settlement Fund in an amount not greater than 30% of the Settlement Fund and for reimbursement of expenses up to a maximum amount of \$175,000, which is approximately \$0.10 per share. Lead Counsel, without further notice to the Settlement Class, may subsequently apply to the Court for fees and expenses incurred in connection with administering and distributing the Settlement proceeds to Settlement Class Members and any proceedings subsequent to the Fairness Hearing.

17. How do I tell the Court that I do not like the Settlement?

If you are a Settlement Class Member, you can tell the Court that you do not agree with any part of the Settlement, the Plan of Allocation, or Lead Counsel's request for attorneys' fees and reimbursement of expenses. You can give reasons why you think the Court should not approve the Settlement. The Court will consider your views. If the Court rejects or modifies the Plan of Allocation and/or the amount of attorneys' fees or expenses requested, the Court may still approve the Settlement.

If you object to the Settlement, you may submit a letter stating your objection. Be sure to include the date(s), price(s), and number(s) of shares of all purchases and sales of Andrx common stock during the Class Period. In addition, be sure to sign the letter, and include your name, address, and telephone number in the letter. This letter should be sent by first class U.S. mail, postage prepaid, and postmarked **no later than March 14, 2008**, to all of the following:

Hon. William P. Dimitrouleas
United States District Court
299 East Broward Blvd.
Room 203F
Fort Lauderdale, FL 33301

Jacqueline Sailer
MURRAY, FRANK & SAILER LLP
275 Madison Avenue
Suite 801
New York, NY 10016

Tracy Nichols
HOLLAND & KNIGHT LLP
701 Brickell Avenue
Suite 3000
Miami, FL 33131

18. What is the difference between objecting and excluding?

Objecting is simply telling the Court that you do not like something about the Settlement, the Plan of Allocation, or Lead Counsel's request for attorneys' fees and reimbursement of expenses. You can object only if you stay in the Settlement Class. *Excluding* yourself is telling the Court that you do not want to be part of the Settlement Class. If you exclude yourself, you have no basis to object because the Action no longer affects you, and you are *not* releasing any claims which you may have.

19. When and where will the Court decide whether to approve the Settlement, the Plan of Allocation, and Lead Counsel's request for attorneys' fees and reimbursement of expenses?

The Court will hold the Fairness Hearing on April 3, 2008 at 1:00 p.m., at the United States District Court, 299 East Broward Blvd, Fort Lauderdale, FL 33301. At the Fairness Hearing, the Court will consider: (a) whether this Action satisfies the applicable prerequisites for class action treatment under Rule 23 of the Federal Rules of Civil Procedure; (b) whether the terms of the Settlement are fair, reasonable and adequate, and in the best interests of the Settlement Class; (c) whether to approve the Plan of Allocation; (d) whether to enter the Order and Final Judgment as provided under the Stipulation; (e) whether to approve the application of Lead Counsel for an award of attorneys' fees and expenses; and (f) such other matters as the Court may deem appropriate. If there are objections, the Court will consider them. At or after the Fairness Hearing, the Court will decide whether to approve the Settlement.

20. Do I have to come to the Fairness Hearing?

No. Lead Counsel will answer questions the Court may have. You are, however, welcome to come at your own expense. If you send an objection, you do not have to come to Court to talk about it. As long as you mailed your written objection on time, the Court will consider it. You may also pay your own lawyer to attend, but it is not necessary.

21. May I speak at the Fairness Hearing?

You may ask the Court for permission to speak at the Fairness Hearing. To do so, you must send a letter saying that it is your "Notice of Intention to Appear in *Lowry v. Andrx Corp.*" Be sure to include your name, address, telephone number, and your signature. Your Notice of Intention to Appear must be postmarked no later than March 14, 2008, and be sent to the Clerk of Court and to Lead Counsel, at the addresses provided in paragraph 17 above. You cannot speak at the Fairness Hearing if you excluded yourself.

22. What will happen if I do nothing at all?

If you are a Settlement Class Member and you do not exclude yourself or timely file a Proof of Claim, you will receive no money from the Settlement. You will not be able to start a lawsuit, continue with a lawsuit, or be part of any other lawsuit against any of the Defendants or the Released Parties about the claims being released in this Action.

23. Are there more details about the Settlement?

This Notice summarizes the proposed Settlement. More details are in the Stipulation. You can get a copy of the Stipulation by writing to Jacqueline Sailer, Esq., Murray, Frank & Sailer LLP, 275 Madison Avenue, Suite 801, New York, New York 10016. The Stipulation is also available at www.murrayfrank.com.

You also can contact the Claims Administrator by toll-free phone at (866) 274-4004; by fax at (610) 565-7985; by mail at Andrx Corporation Securities Litigation, c/o Strategic Claims Services, 600 North Jackson Street, Suite 3, P.O. Box 230, Media, Pennsylvania 19063; or by visiting www.strategicclaims.net.

24. How do I get more information?

Visit Lead Counsel's website at www.murrayfrank.com, for more detailed information concerning the matters involved in this Action and to review the pleadings, the Stipulation, the Orders entered by the Court and the other papers filed in the Action. These papers may also be inspected at the Office of the Clerk of Court for the United States District Court for the Southern District of Florida, during regular business hours.

SPECIAL NOTICE TO SECURITIES BROKERS AND OTHER NOMINEES

If you purchased Andrx common stock on the open market between March 9, 2005 and September 5, 2005, both dates inclusive, for the beneficial interest of a person or organization other than yourself, the Court has directed that, **WITHIN SEVEN (7) DAYS OF YOUR RECEIPT OF THIS NOTICE**, you either: (a) provide to the Claims Administrator the name and last known address of each person or organization for whom or for which you purchased such stock during such time period, preferably on computer-generated mailing labels or electronically setting forth (i) title/registration, (ii) street address, (iii) city/state/zip, or, in the alternative (b) request additional copies of this Notice Package, which will be provided to you free of charge, and within seven (7) days mail the Notice Package directly to the beneficial owners of the common stock referred to herein. If you choose to follow alternative procedure (b), the Court has directed that, upon such mailing, you send a statement to the Claims Administrator confirming that the mailing was made as directed. You are entitled to reimbursement from the Net Settlement Fund of your reasonable expenses actually incurred in connection with the foregoing, including reimbursement of postage expense and the cost of ascertaining the names and addresses of beneficial owners. Those expenses will be paid after the request and submission of appropriate supporting documentation. All communications concerning the foregoing should be addressed to the Claims Administrator:

Andrx Corporation Securities Litigation
c/o Strategic Claims Services
600 North Jackson Street, Suite 3
P.O. Box 230
Media, PA 19063
www.strategicclaims.net

PLEASE DO NOT CONTACT THE CLERK OF COURT OR THE COURT REGARDING THIS NOTICE.

Dated: December 10, 2007

BY ORDER OF THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF FLORIDA

[THIS PAGE INTENTIONALLY LEFT BLANK]

**UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF FLORIDA
FORT LAUDERDALE DIVISION**

| | | |
|---|---|-------------------------------------|
| JERRY LOWRY, on behalf of himself and all others similarly situated, | X | |
| | : | |
| | : | |
| <i>Plaintiff,</i> | : | |
| v. | : | CASE NO.: 05-61640-CIV-DIMITROULEAS |
| ANDRX CORPORATION, and THOMAS P. RICE, | : | |
| | : | |
| <i>Defendants.</i> | : | |
| | : | |
| | X | |

PROOF OF CLAIM AND RELEASE

ALL CLAIMANTS (PERSONS OR ENTITIES WHO PURCHASED SHARES OF THE COMMON STOCK OF ANDRX CORPORATION (“ANDRX”) ON THE OPEN MARKET DURING THE PERIOD MARCH 9, 2005 AND SEPTEMBER 5, 2005, INCLUSIVE (THE “CLASS PERIOD”) ARE URGED TO READ THE NOTICE OF PENDENCY OF PROPOSED CLASS ACTION AND ITS SETTLEMENT (THE “NOTICE”) ACCOMPANYING THIS PROOF OF CLAIM AND RELEASE.

I. INSTRUCTIONS

A. To recover as a Settlement Class Member based on your claims in the above-captioned litigation (the “Action”), you must have purchased Andrx common stock on the open market between March 9, 2005 and September 5, 2005, both dates inclusive, and suffered damages thereby. You must not be a person who is excluded from the Class, as is defined in the Notice. You also must not be a person who requested to be excluded from the Class. If you are a Settlement Class Member and not one of the excluded persons, and wish to participate in the proposed settlement (“Settlement”) of the Action, you must complete and sign this Proof of Claim and Release (“Proof of Claim”). If you fail to file a properly addressed and fully completed Proof of Claim, or fail to provide required documentation, your claim may be rejected and you may be precluded from any recovery from the proposed Settlement.

B. YOU MUST MAIL YOUR COMPLETED AND SIGNED PROOF OF CLAIM POSTMARKED ON OR BEFORE APRIL 10, 2008 TO:

Andrx Corporation Securities Litigation
c/o Strategic Claims Services
600 North Jackson Street, Suite 3
P.O. Box 230
Media, PA 19063
www.strategicclaims.net

C. If you are a Settlement Class Member and did not request exclusion, you will be bound by the terms of any judgment entered in the Action in connection with the Settlement WHETHER OR NOT YOU SUBMIT A PROOF OF CLAIM.

II. CLAIMANT IDENTIFICATION INSTRUCTIONS

A. If you purchased Andrx common stock and registered the certificate in your name, you are the beneficial owner as well as the record purchaser. If, however, you purchased Andrx common stock and the certificate was registered in the name of a third party, such as your stock broker or some other nominee or trustee, you are the beneficial owner even though the third party is the record purchaser listed on Andrx’s records. Proceeds of this Settlement will be distributed to Class members who are beneficial owners of Andrx common stock as described in the accompanying Notice, subject to the terms and conditions of the Stipulation of Settlement described in that Notice.

B. Use Section IV of this form, entitled “Claimant Identification Schedule,” to identify yourself and each owner of record, such as your stock broker, if different from the beneficial owner, of Andrx common stock that forms the basis of this claim. THIS CLAIM MUST BE FILED BY THE ACTUAL BENEFICIAL OWNER(S), OR THE LEGAL REPRESENTATIVE OF SUCH OWNER(S), OF THE COMMON STOCK UPON WHICH THIS CLAIM IS BASED.

C. All joint owners must sign this claim. Executors, administrators, guardians, conservators, and trustees must complete and sign this claim on behalf of persons represented by them and must identify each beneficial owner or

owners for whom they are acting; proof of their authority must accompany this claim and their titles or capacities must be stated.

D. The Social Security (or Taxpayer Identification) number and telephone number of the beneficial owner must be provided.

E. Failure to provide the foregoing information could delay verification or result in the rejection of the claim.

III. INSTRUCTIONS FOR SCHEDULE OF TRANSACTIONS

A. Use Section V of this form, entitled "Schedule of Transactions," to supply all required details of your transactions (open market purchases and sales) in Andrx common stock that took place during the period from March 9, 2005 to December 4, 2005, inclusive.

B. If you need more space, attach separate, numbered sheets giving all of the required information in substantially the same form. Print your name and Social Security or Taxpayer Identification number at the top of each additional sheet.

C. On the schedules, provide all of the requested information with respect to all of your open market purchases and sales of Andrx common stock that took place at any time during the Class Period, whether such transactions resulted in a profit or a loss.

D. The failure to report all such transactions may result in the rejection of your claim.

E. List each transaction during the Class Period separately and in the order in which they took place, *by trade date*, beginning with the earliest. You must accurately provide the month, day, and year of each transaction you list, as well as the purchase and/or sales price, excluding commissions, taxes, and other fees. If you do not have this information, your broker may be able to help you find it.

F. COPIES OF BROKER'S CONFIRMATIONS, BROKER'S ACCOUNT STATEMENTS, OR OTHER ACCEPTABLE DOCUMENTATION OF YOUR TRANSACTIONS IN ANDRX COMMON STOCK MUST BE ATTACHED TO YOUR CLAIM. DO NOT SEND ORIGINAL DOCUMENTS OR SHARES OF STOCK. If you no longer have copies of your broker's confirmations or statements, your broker may be able to get you copies. A complete list of acceptable supporting documentation can be found on the Claims Administrator's website: www.strategicclaims.net.

G. Any claims submitted that contain more than 50 transactions during the Class Period are requested to be filed electronically and to provide all the purchase and sale information required in the Schedule of Transactions. For a copy of instructions and parameters concerning such a submission, contact the Claims Administrator: (1) at the website address above, and click on Electronic Filing Information; (2) by phone at (866) 274-4004; or (3) by fax at (610) 565-7985.

IV. CLAIMANT IDENTIFICATION SCHEDULE

Claims must be received by the Claims Administrator postmarked no later than April 10, 2008.

Please Type or Print

| | | | | | | | | | | | | | | | | | | | | | | | | |
|---|--|--|-------------------------|--|--|--|--|--|-----------|--|--|-------------------------|--|--|--|--|-------------------------|-----------|--|--|------------|--|--|--|
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Beneficial Owner's Name (as it appears on your brokerage statement) | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Joint Beneficial Owner's Name (as it appears on your brokerage statement) | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Street Address | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| City | | | | | | | | | | | | | | | State or Province | | Zip Code or Postal Code | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Foreign Province | | | | | | | | | | | | | | | Foreign Country | | | | | | | | | |
| Social Security Number: [][][]-[][]-[][][][] | | | | | | | | | | | | | | | OR Taxpayer Identification Number: [][]-[][][][][][] | | | | | | | | | |
| Area Code | | | Telephone Number (Work) | | | | | | Area Code | | | Telephone Number (Home) | | | | | | Area Code | | | Fax Number | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| E-Mail Address | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Record Owner's Name and Address (if different from beneficial owner listed above) | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |

Specify one of the following.

Claimant holder of Andrx Common Stock is:

- ___ A. Individual Claimant: I am a claimant acting in my own interest, and am the sole owner of the shares.
- ___ B. Joint Claimants: We are claimants acting jointly.
- ___ C. Corporate Claimant: I am the _____ of _____, a corporation whose address is _____. I am authorized to make this claim on behalf of the corporation. The corporation is the owner of the shares.
- ___ D. IRA Claimant: I am a claimant acting on behalf of my IRA. The shares are held in my IRA.
- ___ E. Partnership Claimant: I am a partner of _____, a partnership whose business address is _____. I am authorized to make this claim on behalf of the partnership. The partnership is the owner of the shares.
- ___ F. Decedent's Estate Claimant: I am the *executor* or the *administrator* (circle which) of the estate of _____, whose last address was _____.
(Valid proof of authority must accompany this claim.)
- ___ G. Trust Claimant: I am a trustee of _____, a trust authorized under the laws of _____. I am authorized to make this claim on behalf of the trust. The trust is the owner of the shares.
- ___ H. Custodial or Guardian Claimant: I am the *custodian* or the *guardian* (circle which) for whose address is _____. (Valid proof of authority must accompany this claim.)
- ___ I. Other: (Specify) _____.

V. SCHEDULE OF TRANSACTIONS IN ANDRX COMMON STOCK

A. State the total number of shares of Andrx common stock owned at the close of trading on March 8, 2005, long or short (*must be documented; see III above, Instruction G*): _____

B. Separately list each and every open market purchase of Andrx common stock during the period March 9, 2005 to December 4, 2005, inclusive, and provide the following information (*must be documented; see III above, Instruction G*):

| Date(s) of Purchase (List Chronologically) (Month / Day / Year) | Number of Shares Purchased | Total Cost (excluding commissions, taxes, and fees) |
|---|-------------------------------|---|
| - - | | \$. |
| - - | | \$. |
| - - | | \$. |
| - - | | \$. |

C. Separately list each and every sale of Andrx common stock during the period March 9, 2005 to December 4, 2005, inclusive, and provide the following information (*must be documented; see III above, Instruction G*):

| Date(s) of Sale (List Chronologically) (Month / Day / Year) | Number of Shares Sold | Net Proceeds (excluding commissions, taxes, and fees) |
|---|--------------------------|---|
| - - | | \$. |
| - - | | \$. |
| - - | | \$. |
| - - | | \$. |

State the total number of shares of Andrx common stock owned at the close of trading on December 4, 2005, long or short (*must be documented; see III above, Instruction G*): _____

If additional space is needed, attach separate, numbered sheets, giving all required information, substantially in the same format, and print your name and Social Security or Taxpayer Identification number at the top of each sheet.

YOU MUST ALSO READ AND SIGN THE RELEASE ON PAGE 15.

IMPORTANT: FAILURE TO ATTACH SUPPORTING DOCUMENTATION MAY PREVENT YOU FROM RECEIVING ANY DISTRIBUTION UNDER THE SETTLEMENT

VI. SUBMISSION TO JURISDICTION OF COURT

I/We submit this Proof of Claim under the terms of the Stipulation of Settlement described in the Notice. I/we also submit to the jurisdiction of the United States District Court for the Southern District of Florida with respect to my/our claim as a Settlement Class Member and for purposes of enforcing the release set forth herein. I/we further acknowledge that I am/we are bound by and subject to the terms of any judgment that may be entered in the Action. I/we agree to furnish additional information to Lead Counsel to support this claim if requested to do so. I/we authorize Andrx or any brokerage house with whom I/we transacted business to release to Lead Counsel, or their designee, upon their request and without notice to me/us, any and all information relating to any purchase or sale of Andrx common stock by me/us during the Class Period.

VII. RELEASE

A. I/We hereby acknowledge full and complete satisfaction of, and do hereby fully, finally and forever settle, release and discharge any and all Released Claims (as defined below) against any and all of the Defendants (as defined below) and the Released Parties (as defined below).

B. “Released Claims” means any and all claims, demands, rights, causes of action or liabilities, of every nature and description whatsoever, whether based in law or equity, on federal, state, local, statutory or common law, or any other law, rule or regulation, known or Unknown Claims (as defined herein), accrued or not accrued, at law or in equity, which have been or could have been asserted individually by any Plaintiff and/or any Class Member in the Action against Defendants or any Released Parties which relate to, arise out of, or are based upon (a) any open market purchase of Andrx common stock during the Class Period and (b) the facts, matters, transactions or circumstances alleged or that could have been alleged in the Action.

C. “Unknown Claims” means any Released Claims which any Settling Party, and any or all other Persons and entities whose claims are being released, does not know or suspect to exist in his, her or its favor at the time of the release of the Released Parties which, if known by him, her, or it, might have affected his, her, or its settlement with and release of the Released Parties, or might have affected his, her, or its decision not to object to this settlement. Upon the Effective Date, the Settling Parties, and all other Persons and entities whose claims are being released, shall be deemed to have, and shall have, expressly waived and relinquished, to the fullest extent permitted by law, the provisions, rights and benefits of §1542 of the California Civil Code, which provides as follows:

A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.

The Lead Plaintiff and Defendants have, and each of the Class Members shall be deemed to have and—by operation of the Judgment—shall have, expressly waived any and all provisions, rights and benefits conferred by any law of any state or territory of the United States, or principle of common law, which is similar, comparable and equivalent to California Civil Code §1542. The Settling Parties may hereafter discover facts in addition to or different from those which he, she, or it now knows or believes to be true with respect to the subject matter of the Released Claims, but each Lead Plaintiff and Defendant shall expressly and each Class Member, upon the Effective Date, shall be deemed to have, and—by operation of the Judgment—shall have, fully, finally, and forever settled and released any and all Released Claims, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts. Lead Plaintiff and Defendants acknowledge, and the Class Members shall be deemed by operation of the Judgment to have acknowledged, that the foregoing waiver of Unknown Claims was separately bargained for and a key element of the settlement of which this release is a part.

D. “Defendants” means Andrx Corporation and Thomas P. Rice.

E. “Released Parties” means Defendants and the Related Parties. “Related Parties,” as defined in the Stipulation, means as to Andrx, each of Andrx’s past or present directors, officers, employees, agents, insurers, attorneys, accountants or auditors, legal representatives, predecessors, successors-in-interest, parents (including Watson Pharmaceuticals Inc.), subsidiaries, divisions, joint ventures, assigns, or any entity in which Andrx has a controlling interest; and means, as to Thomas P. Rice, any member of his immediate family, spouse, insurer, heir, or any trust of which Rice is the settler or which is for the benefit of Rice and/or member(s) of his family.

F. I/We hereby warrant and represent that I/we have not assigned or transferred or purported to assign or transfer, voluntarily or involuntarily, any matter released pursuant to this Release or any other part or portion thereof.

G. This Release shall be of no force or effect unless the United States District Court for the Southern District of Florida approves the Stipulation of Settlement filed with the Court (the "Stipulation") and unless the Stipulation becomes effective as to Defendants on the Effective Date (as defined in the Stipulation).

III. CERTIFICATION

I/We certify that I/we believe in good faith that I am/we are a Settlement Class Member, as defined in the Notice, or am/are acting for such person; that I/we have read and understood the contents of the Notice; that I/we have not submitted a Request for Exclusion seeking to be excluded from the Class; that I/we believe that I am/we are entitled to receive a portion of the Net Settlement Fund; and that the foregoing information is true, accurate, and complete to the best of my/our knowledge, information, and belief.

Federal law provides that the filing of a false claim is punishable by a fine of not more than \$10,000 or imprisonment for not more than five years, or both.

I/We certify that I am/we are NOT subject to backup withholding under the provisions of Section 3406(a)(1)(c) of the Internal Revenue Code.

NOTE: If you have been notified by the Internal Revenue Service that you are subject to backup withholding, please strike out the word "NOT" in the certification above.

I/We declare under penalty of perjury under the laws of the United States that the foregoing information supplied by the undersigned and the supporting documentation attached hereto are true and correct, that I/we wish to enter into the Release, and that this Proof of Claim form was executed this _____ day of _____ (month), _____ (year)

in _____, _____.
(City) (State/Country)

Signature of Claimant

Signature of person signing on behalf of claimant

(Print your name here)

(Print your name here)

Signature of Joint Claimant, if any

(Capacity of persons signing on behalf of claimant, e.g., Executor, Custodian, etc.)

(Print your name here)

IMPORTANT: IF THIS CLAIM IS ON BEHALF OF JOINT OWNERS, ALL JOINT OWNERS MUST SIGN.

**ACCURATE CLAIMS PROCESSING TAKES A
SIGNIFICANT AMOUNT OF TIME
THANK YOU FOR YOUR PATIENCE.**

In re Andrx Corporation Securities Litigation
c/o Strategic Claims Services
Claim Administrator
P.O. Box 230
Media, PA 19063

FIRST CLASS MAIL
U.S. POSTAGE
PAID
PERMIT NO. 138
PHILADELPHIA, PA

FIRST CLASS MAIL

PLEASE FORWARD—IMPORTANT LEGAL NOTICE

Reminder Checklist:

1. Please sign the above Release and Certification.
2. Remember to attach only **copies** of acceptable supporting documentation, a complete list of which can be found on the Claims Administrator's website.
3. Do not send original common stock certificates.
4. Keep a copy of the completed claim form and documentation for your records.
5. If you desire an acknowledgment of receipt of your claim form, please send it Certified Mail, Return Receipt Requested, or its equivalent. **You will bear all risks of delay or non-delivery of your claim.**
6. If your address changes in the future, or if these documents were sent to an old or incorrect address, please send us **written** notification of your new address.
7. If you have any questions or concerns regarding your claim, please contact the Claims Administrator at:

Andrx Corporation Securities Litigation
c/o Strategic Claims Services
600 North Jackson Street, Suite 3
P.O. Box 230
Media, PA 19063
www.strategicclaims.net